Bose, Prithviraj <br/><br/>
JAK2 inhibitors for myeloproliferative neoplasms: what is next?  [electronic resource] 

 -  Blood  07 2017 
 - 115-125 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1528-0020 
<br/><br/><label>Standard No.: </label>10.1182/blood-2017-04-742288  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--therapeutic use<br/>Bridged-Ring Compounds--therapeutic use<br/>Gene Expression<br/>Humans<br/>Janus Kinase 1--antagonists & inhibitors<br/>Janus Kinase 2--antagonists & inhibitors<br/>Mutation<br/>Nitriles<br/>Patient Safety<br/>Polycythemia Vera--drug therapy<br/>Primary Myelofibrosis--drug therapy<br/>Protein Kinase Inhibitors--therapeutic use<br/>Pyrazoles--therapeutic use<br/>Pyrimidines--therapeutic use<br/>Randomized Controlled Trials as Topic<br/>Thrombocythemia, Essential--drug therapy<br/>Treatment Outcome